

Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

F4/80 antibody [Cl:A3-1]

RRID:AB_1140040

Type: Antibody

Proper Citation

Abcam Cat# ab6640, RRID:AB_1140040

Antibody Information

URL: http://antibodyregistry.org/AB_1140040

Proper Citation: Abcam Cat# ab6640, RRID:AB_1140040

Target Antigen: F4/80 antibody [Cl:A3-1]

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Immunoprecipitation; Immunofluorescence; Immunohistochemistry; Flow Cytometry; Western Blot; Immunocytochemistry; Immunohistochemistry - fixed; Flow Cyt, ICC/IF, IHC-FoFr, IHC-Fr, IHC-P, IHC-R, IP, RIA, WB; Immunohistochemistry - frozen; Radioimmunoassay

Info: Used by Czech Centre for Phenogenomics

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: F4/80 antibody [Cl:A3-1]

Description: This monoclonal targets F4/80 antibody [Cl:A3-1]

Target Organism: mouse, human

Antibody ID: AB_1140040

Vendor: Abcam

Catalog Number: ab6640

Record Creation Time: 20250819T235741+0000

Record Last Update: 20250820T065652+0000

Ratings and Alerts

- Used by Czech Centre for Phenogenomics - Czech Centre for Phenogenomics
<https://www.phenogenomics.cz/>

No alerts have been found for F4/80 antibody [Cl:A3-1].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 166 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kuai Y, et al. (2026) Targeted PGC-1 γ gene delivery by GV-assisted ultrasound cavitation for renal ischemia-reperfusion injury therapy. *iScience*, 29(1), 114374.

Niravath P, et al. (2026) A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL). *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1697.

Xu Y, et al. (2026) A dysregulated hepcidin-iron axis impairs antiviral immunity and induces lethal liver pathology in neonates. *Immunity*, 59(1), 79.

Zhang Y, et al. (2026) A sequential dual-drug delivery system for multi-target inhibition of subretinal fibrosis. *Journal of nanobiotechnology*, 24(1).

Peng H, et al. (2026) Fucosyltransferase 8-mediated core fucosylation of krüppel-like factor 6 exacerbates myocardial ischaemia/reperfusion injury via promoting macrophage M1 polarization. *British journal of pharmacology*, 183(17), 5284.

Lynch RW, et al. (2026) IL-4 treatment induces apoptosis of blood monocytes and proliferation of recruited injury-associated macrophages to resolve liver injury. *Cell reports*, 45(4), 117136.

Liang Z, et al. (2026) Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid recycling. *Cancer cell*, 44(6), 1235.

Leduc-Pessah H, et al. (2026) Runx1 transcription factor modulates opioid analgesia and withdrawal in humans and rodents. *Neuron*, 114(5), 903.

Wang H, et al. (2026) Targeting the macrophage mechanosensing regulator CKAP4 accelerates the inflammatory-to-proliferative transition in wound healing. *Cell reports*, 45(6), 117395.

Xu Y, et al. (2026) IRE1 β regulates macrophage phagocytosis in immune thrombocytopenia through NR1D1 mRNA decay and lysosomal biogenesis. *Cell reports*, 45(3), 117083.

Assad N, et al. (2026) Crosstalk between circulating DPP3 and immune cells in the context of cardio-systemic stress. *iScience*, 29(3), 115114.

Feng Q, et al. (2025) Macrophage extracellular traps as key mediators of scleral remodeling in myopia induced by hypoxia and activated platelets. *Cell reports*, 44(6), 115771.

Jiang Y, et al. (2025) Phosphatase PHLPP1 is an alveolar-macrophage-intrinsic transcriptional checkpoint controlling pulmonary fibrosis. *Cell reports*, 44(3), 115399.

Wang CA, et al. (2025) Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells. *Molecular cancer*, 24(1), 25.

Kaylan KB, et al. (2025) 12-Lipoxygenase Inhibition Improves Glycemia and Obesity-associated Inflammation in Male Human Gene Replacement Mice. *Endocrinology*, 166(6).

Salomó Coll C, et al. (2025) ER-phagy and proteostasis defects prime pancreatic epithelial state changes in KRAS-mediated oncogenesis. *Developmental cell*.

Dumesic PA, et al. (2025) RBM43 controls PGC1 β translation and a PGC1 β -STING signaling axis. *Cell metabolism*, 37(3), 742.

Amuso VM, et al. (2025) Fibroblast-Mediated Macrophage Recruitment Supports Acute Wound Healing. *The Journal of investigative dermatology*, 145(7), 1781.

Yuan Y, et al. (2025) Targeting insulin-like growth factor 1 receptor restricts development and severity of secondary lymphedema in mice. *iScience*, 28(3), 111948.

Hansen D, et al. (2025) Hepatic stellate cells regulate liver fatty acid utilization via plasmalemma vesicle-associated protein. *Cell metabolism*, 37(4), 971.